News | 23 November 2024
Amalgamation of Gujarat Themis Biosyn with Themis Medicare
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
Modernization and supply chain diversity drive new growth
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
Total Income in Q2 FY25 stood at Rs. 532.18 crore
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Subscribe To Our Newsletter & Stay Updated
